Showing results (51-60 of 969) with videos related to

Sort By:
Pageof 97
American Journal of Hematology|November 2, 2012
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaNaval Daver, Paolo Strati, Elias Jabbour, et al.
Leukemia Research|July 18, 2015
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phaseTalha Badar, Hagop M Kantarjian, Farhad Ravandi, et al.
Current Opinion in Hematology|January 11, 2017
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategiesRita Assi, Srdan Verstovsek, Naval Daver
American Journal of Hematology|March 4, 2015
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaJuan Ouyang, Maitrayee Goswami, Guilin Tang, et al.
Frontiers in Oncology|April 26, 2021
IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaClaudio Cerchione, Alessandra Romano, Naval Daver, et al.
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Pageof 97